Our Science – Figg Website
William Douglas Figg Sr., Pharm.D.
Selected Publications |
 |
| 1)
Hall C, Troutman SM, Price DK, Figg WD, Kang MH. Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. Clin Genitourin Cancer. 11: 10-9, 2013. [Journal] |
|
| 2)
Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C, Kapanadze T, Compton K, Figg WD, Greten TF. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol. Immunother. 62: 299-307, 2013. [Journal] |
|
| 3)
Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 121: 476-84, 2013. [Journal] |
|
| 4)
Johnson LM, Price DK, Figg WD. Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment. Cancer Biol. Ther. 14: 90-1, 2013. [Journal] |
|
| 5)
Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2012. [Journal] |
|
| 6)
Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin. Cancer Res. 18: 4820-9, 2012. [Journal] |
|
| 7)
Chau CH, Figg WD. Aflibercept in pediatric solid tumors: moving beyond the trap. Clin. Cancer Res. 18: 4868-71, 2012. [Journal] |
|
| 8)
Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, Hsing AW. Associations of serum sex steroid hormone and 5a-androstane-3a,17ß-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. Cancer Epidemiol. Biomarkers Prev. 21: 1823-32, 2012. [Journal] |
|
| 9)
Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 5: 35, 2012. [Journal] |
|
| 10)
Sissung TM, Reece KM, Spencer S, Figg WD. Contribution of the OATP1B subfamily to cancer biology and treatment. Clin. Pharmacol. Ther. 92: 658-60, 2012. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/8/2013.
